Want to see HK:6821 full AI Analyst Report?
6821 Stock Chart & Stats
HK$115.50
HK$2.70(2.34%)
At close: 4:00 PM EDT
HK$115.50
HK$2.70(2.34%)
Day’s Range― - ―
52-Week RangeHK$69.20 - HK$139.70
Previous CloseN/A
Volume591.20K
Average Volume (3M)640.69K
Market Cap
HK$70.20B
Enterprise ValueHK$31.73K
Total Cash (Recent Filing)HK$6.61B
Total Debt (Recent Filing)HK$514.12M
Price to Earnings (P/E)59.3
Beta1.27
Next Earnings
Nov 04, 2026Next Dividend Ex-DateN/A
Dividend Yield1.14%
Share Statistics
EPS (TTM)2.90
Shares Outstanding27,834,510
10 Day Avg. Volume442,016
30 Day Avg. Volume640,687
Financial Highlights & Ratios
PEG Ratio1.08
Price to Book (P/B)1.29
Price to Sales (P/S)3.40
P/FCF Ratio165.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$146.35Price Target Upside26.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)4.52
Revenue Forecast (FY)HK$9.41B
Bulls Say, Bears Say
Bulls Say
Integrated CDMO Service ModelAsymchem’s integrated CDMO model supports customers from development through commercial production. Serving multiple stages can deepen customer relationships, broaden revenue opportunities and create recurring manufacturing work when drugs reach approval.
Strong Revenue ReboundThe sharp TTM revenue rebound indicates renewed business activity and customer demand after weaker periods. Sustained growth would improve operating scale and provide a stronger base for recovering profitability if capacity utilization and project mix improve.
Very Conservative Balance SheetMinimal leverage materially limits refinancing and solvency risk while preserving financial flexibility. A strong equity base gives Asymchem capacity to fund manufacturing investment, absorb volatility and pursue growth without relying heavily on debt.
Bears Say
Sustained Margin CompressionLower gross and net margins show that the recent revenue rebound is generating less profit than earlier growth periods. If unfavorable project mix, pricing pressure or underutilized capacity persists, earnings recovery may lag revenue growth.
Negative Free Cash FlowNegative free cash flow means operating cash is currently insufficient after investment spending and working-capital needs. Continued weak conversion could constrain internally funded expansion and make reported earnings less useful as a measure of financial strength.
Cooling Profitability And ReturnsLower net income despite sharply higher revenue, together with reduced ROE, indicates weaker earnings productivity and a less favorable business mix. This may limit the benefit of top-line expansion until margins and capital efficiency recover.
Asymchem Laboratories (Tianjin) Co., Ltd. Class H News
6821 FAQ
What was Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s price range in the past 12 months?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H lowest stock price was HK$69.20 and its highest was HK$139.70 in the past 12 months.
What is Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s market cap?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s market cap is HK$70.20B.
When is Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s upcoming earnings report date?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s upcoming earnings report date is Nov 04, 2026 which is in 69 days.
How were Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s earnings last quarter?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H released its earnings results on Aug 24, 2026. The company reported HK$0.35 earnings per share for the quarter, beating the consensus estimate of HK$0 by HK$0.35.
Is Asymchem Laboratories (Tianjin) Co., Ltd. Class H overvalued?
According to Wall Street analysts Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s price is currently Undervalued.
Does Asymchem Laboratories (Tianjin) Co., Ltd. Class H pay dividends?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H pays a Annually dividend of HK$1.495 which represents an annual dividend yield of 1.14%. See more information on Asymchem Laboratories (Tianjin) Co., Ltd. Class H dividends here
What is Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s EPS estimate?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s EPS estimate is 0.
How many shares outstanding does Asymchem Laboratories (Tianjin) Co., Ltd. Class H have?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H has 27,834,510 shares outstanding.
What happened to Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s price movement after its last earnings report?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H reported an EPS of HK$0.35 in its last earnings report, beating expectations of HK$0. Following the earnings report the stock price went down -7.262%.
Which hedge fund is a major shareholder of Asymchem Laboratories (Tianjin) Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:6821
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Asymchem Laboratories (Tianjin) Co., Ltd. Class H Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$146.35 (26.71% Upside)
HK$146.35 (26.71% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
70.63%
12-Months-Change
Fundamentals
Return on Equity
1.14%
Trailing 12-Months
Asset Growth
10.90%
Trailing 12-Months
Company Description
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
Asymchem Laboratories (Tianjin) Co., Ltd. functions as a Contract Development and Manufacturing Organization (CDMO), offering its services to clients across Mainland China and internationally. The company delivers extensive drug research, development, and manufacturing solutions specifically tailored for pharmaceutical and biotechnology enterprises. Their offerings are comprehensive, covering the entire lifecycle from early clinical stages through to full commercialization, including R&D and cGMP compliant production of advanced intermediates, active pharmaceutical ingredients (APIs), and finished formulations, alongside clinical research support. Furthermore, Asymchem engages in pharmaceutical analysis and testing, the sale and distribution of medicinal products, and active participation in pharmaceutical science and technology innovation. The company was founded in 1999 and maintains its headquarters in Tianjin, China.
Asymchem Laboratories (Tianjin) Co., Ltd. Class H (6821) Earnings & Revenues
6821 Stock 12 Month Forecast
Average Price Target
HK$146.35
▲(26.71% Upside)
Technical Analysis
Genscript Biotech
―
Wuxi Biologics (Cayman)
―
Pharmaron Beijing Co., Ltd. Class H
―
Frontage Holdings Corp.
―
Viva Biotech Holdings
―